Long-Term Data from the TEAM Trial Support Individualized Adjuvant Endocrine Therapy Strategy for Postmenopausal Women with HR-Positive Early Breast Cancer

TON Web Exclusives - Breast Cancer

The Tamoxifen Exemestane Adjuvant Multinational (TEAM) clinical trial was a multicenter, open-label, randomized, controlled phase 3 trial that enrolled postmenopausal women with early-stage HR-positive breast cancer from 9 countries.1,2 Patients in this trial were randomized in a 1:1 ratio to either 5 years of exemestane at 25 mg once daily (N = 4904) or tamoxifen at 20 mg once daily for 2.5 to 3.0 years followed by exemestane 25 mg once daily (N = 4875) for a total of 5 years. Patients had completed local treatment with curative intent, and endocrine therapy was started within 10 weeks after surgery and the end of chemotherapy, if indicated. After a median follow-up of 5 years, there were no significant differences in disease-free survival (DFS), overall survival (OS), or relapse-free survival between the 2 groups of patients.1,2

The extension trial included results from 10 years of follow-up on 3045 patients in the intent-to-treat (ITT) analysis for sequential therapy (tamoxifen/exemestane) and 3075 patients in the ITT analysis for exemestane alone.1 The 10-year DFS was not significantly different between the 2 groups (67% in each arm; P = .39). In addition, the 10-year OS was not significantly different between the groups: 74% with exemestane and 73% with sequential therapy (P = .74). The researchers also reported no difference in the cumulative incidence of distant recurrent disease between the groups (16% with exemestane vs 18% with sequential therapy; P = .15). A small benefit was reported for exemestane monotherapy with regard to cumulative incidence of any breast cancer recurrence—20% recurrence with exemestane versus 22% with sequential therapy.1

The researchers concluded that, “The long-term findings of the TEAM trial confirm that both exemestane alone and sequential treatment with tamoxifen followed by exemestane are reasonable options as adjuvant endocrine therapy in postmenopausal patients with HR-positive early breast cancer. These results suggest that the opportunity to individualise adjuvant endocrine strategy accordingly, based on patient preferences, comorbidities, and tolerability, might be possible.”

References
1. Derks MGM, Blok EJ, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1211-1220.
2. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377:321-331.

Related Items
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Breast Cancer
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Breast Cancer
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Breast Cancer
Explaining Treatment Regimens to Patients with HR+/HER2- Metastatic Breast Cancer
Thomas Bachelot, MD, PhD
Video Library published on July 19, 2018 in Breast Cancer, Video
HR+/HER2- Metastatic Breast Cancer: Common Presenting Symptoms
Hope S. Rugo, MD
Video Library published on July 19, 2018 in Breast Cancer, Video
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Adverse Effects, Breast Cancer
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
TOP Web Exclusives published on April 7, 2018 in Breast Cancer, Online Only
Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Breast Cancer, Drug Updates & News, ESMO
Last modified: January 16, 2018